Literature DB >> 25319469

Effect of a single injection of testosterone enanthate on 17β estradiol and bone turnover markers in hypogonadal male patients.

V Camozzi1, G Bonanni2, A Frigo3, M Piccolo4, S Ferasin5, M Zaninotto6, M Boscaro7, G Luisetto8.   

Abstract

PURPOSE: Several clinical studies testify the critical role played by estrogens in male bone metabolism. The aim of our study is to assess the effect of a single injection of testosterone enanthate in a group of hypogonadal men on 17β estradiol serum levels and some bone metabolic parameters.
METHOD: Twenty-one hypogonadal males were given one testosterone enanthate injection (250 mg). Blood samples were drawn before the injection and after 1, 2 and 3 weeks. The following variables were measured: Total testosterone (TT), 17β estradiol (17β E2), Sex hormone binding globulin, total alkaline phosphatase, osteocalcin, and C-telopeptide of type I collagen (CTx).
RESULTS: After testosterone injection, both TT and 17β E2 increased, peaking 1 week after the injection. Individual observation of the response of 17β E2 to testosterone showed that a subgroup (n = 9) failed to respond with any increase in 17β E2 at any of the weekly tests (group E2-), while the remainder (n = 12) showed a significant increase in 17β E2, which reached a mean value three times higher than at baseline (group E2+). The E2- patients reached a TT peak lower than that observed in the E+ group. CTx serum levels declined progressively in the E2+ group, reaching the significance (p = 0.03) at the end of the study, while it did not change in E- group.
CONCLUSION: This study suggests that a single injection of testosterone might have different effects on the production of endogenous estrogens, and a significant reduction of bone resorption parameters takes place only in the patients who show a significant increase of 17ß estradiol in response to testosterone administration.

Entities:  

Keywords:  Bone metabolism; Bone turnover markers; Estrogens; Hypogonadism; Testosterone

Mesh:

Substances:

Year:  2014        PMID: 25319469     DOI: 10.1007/s40618-014-0183-5

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  43 in total

Review 1.  Clinical review 24: Androgens in the aging male.

Authors:  A Vermeulen
Journal:  J Clin Endocrinol Metab       Date:  1991-08       Impact factor: 5.958

2.  Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency.

Authors:  J P Bilezikian; A Morishima; J Bell; M M Grumbach
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

3.  Estrogen receptor α in osteocytes regulates trabecular bone formation in female mice.

Authors:  Shino Kondoh; Kazuki Inoue; Katsuhide Igarashi; Hiroe Sugizaki; Yuko Shirode-Fukuda; Erina Inoue; Taiyong Yu; Jun K Takeuchi; Jun Kanno; Lynda F Bonewald; Yuuki Imai
Journal:  Bone       Date:  2013-12-10       Impact factor: 4.398

4.  Therapeutic role of androgens in the treatment of osteoporosis in men.

Authors:  L Katznelson
Journal:  Baillieres Clin Endocrinol Metab       Date:  1998-10

5.  Hormone profiles after intramuscular injection of testosterone enanthate in patients with hypogonadism.

Authors:  Ryuto Nakazawa; Katsuyuki Baba; Masaru Nakano; Takuyuki Katabami; Nobuhiko Saito; Takesi Takahashi; Teruaki Iwamoto
Journal:  Endocr J       Date:  2006-05-19       Impact factor: 2.349

6.  Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study.

Authors:  Hermien W Goderie-Plomp; Marjolein van der Klift; Willem de Ronde; Albert Hofman; Frank H de Jong; Huibert A P Pols
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

7.  Dihydrotestosterone stimulates proliferation and differentiation of fetal calvarial osteoblasts and dural cells and induces cranial suture fusion.

Authors:  Ines C Lin; Alison E Slemp; Catherine Hwang; Miguel Sena-Esteves; Hyun-Duck Nah; Richard E Kirschner
Journal:  Plast Reconstr Surg       Date:  2007-10       Impact factor: 4.730

8.  Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts.

Authors:  Takashi Nakamura; Yuuki Imai; Takahiro Matsumoto; Shingo Sato; Kazusane Takeuchi; Katsuhide Igarashi; Yoshifumi Harada; Yoshiaki Azuma; Andree Krust; Yoko Yamamoto; Hiroshi Nishina; Shu Takeda; Hiroshi Takayanagi; Daniel Metzger; Jun Kanno; Kunio Takaoka; T John Martin; Pierre Chambon; Shigeaki Kato
Journal:  Cell       Date:  2007-09-07       Impact factor: 41.582

9.  Estrogen-specific action on bone geometry and volumetric bone density: longitudinal observations in an adult with complete androgen insensitivity.

Authors:  Youri Taes; Bruno Lapauw; Sara Vandewalle; Hans Zmierczak; Stefan Goemaere; Dirk Vanderschueren; Jean-Marc Kaufman; Guy T'Sjoen
Journal:  Bone       Date:  2009-04-17       Impact factor: 4.398

10.  Crosstalk between Wnt/β-catenin and estrogen receptor signaling synergistically promotes osteogenic differentiation of mesenchymal progenitor cells.

Authors:  Yanhong Gao; Enyi Huang; Hongmei Zhang; Jinhua Wang; Ningning Wu; Xian Chen; Ning Wang; Sheng Wen; Guoxin Nan; Fang Deng; Zhan Liao; Di Wu; Bosi Zhang; Junhui Zhang; Rex C Haydon; Hue H Luu; Lewis L Shi; Tong-Chuan He
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

View more
  3 in total

1.  How to define hypogonadism? Results from a population of men consulting for sexual dysfunction.

Authors:  G Rastrelli; G Corona; M Tarocchi; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-01-05       Impact factor: 4.256

2.  Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry.

Authors:  G Rastrelli; L Giovannini; A E Calogero; D Gianfrilli; E Serra; A Pizzocaro; V A Giagulli; G Motta; G Vancieri; A Sperandio; S Andò; R Selice; G Luca; F Cocchiara; D Canale; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-04-01       Impact factor: 4.256

3.  Dimethandrolone Undecanoate, a Novel, Nonaromatizable Androgen, Increases P1NP in Healthy Men Over 28 Days.

Authors:  Arthi Thirumalai; Fiona Yuen; John K Amory; Andrew N Hoofnagle; Ronald S Swerdloff; Peter Y Liu; Jill E Long; Diana L Blithe; Christina Wang; Stephanie T Page
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.